REG - BSF Enterprise PLC - Successful Prototypes of Lab-Grown Fillets of Meat

BSF EnterpriseAnnouncement

15/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221115:nRSO3737Ga&default-theme=true

RNS Number : 3737G  BSF Enterprise PLC  15 November 2022

15 November 2022

BSF Enterprise PLC

("BSF" or the "Company")

 

Successful Prototypes of Lab-Grown Fillets of Meat

Ground-breaking Prototypes Exceed Expectations

 

BSF Enterprise plc, an investment company focused on unlocking the next
generation of biotech solutions, announces that its wholly owned subsidiary,
3D Bio-Tissues, has reached another milestone in successfully producing three
small prototype fillets of cultivated meat. This is a major step forward
toward 3D Bio-Tissues' objective of producing the UK's first full-scale
cultivated meat fillet, which it expects to showcase in the coming months.

 

3D Bio-Tissues (3DBT) produced three small meat fillets of approximately 30 mm
in height and 15 mm in diameter, with an average weight of 5 grammes,
utilising innovative proprietary methods. It then tested the prototypes across
a variety of attributes to ascertain their quality and similarity to
conventional meat, with comprehensively positive results.

 

In their raw state the lab-grown fillets exhibited structural integrity and
resistance to breaking when being manipulated and compressed. The fillets
resembled conventional farm grown meat to touch with similar consistency and
elasticity and no obvious aroma.

 

Two of the fillets were then pan fried, cooking rapidly and throughout while
maintaining integrity and shape and exhibiting only minimal shrinkage, as
would be expected during the preparation of high-quality farm grown meat. The
fillets seared easily, showed heavy caramelisation with charring and crisping
on the surface, and the aromas were identical to those of barbecued meat. In
summary, the test results met, and in many areas exceeded, our expectations in
all respects.

 

A further significant development was that the prototype fillets were all
produced without the use of conventional plant-based scaffolds or fillers, as
have been universally adapted by the industry to date in order to ensure
structural integrity. The fillets were therefore 100% meat, leading the
Company to believe this is one of the world's first 100% cultivated meat
fillets to be produced.

 

This was made possible as the fillets were cultured in 3DBT's patented,
serum-free and animal-free cell booster, City-mix(TM). City-mix(TM) enhances
growth of cells and tissues to the point that the need for a scaffold is
eliminated. City-mix(TM) is a critical intellectual property component of the
Company's offering, providing clear competitive differentiation and world
leading technology.

 

As previously announced, the Company expects to produce a larger scale
prototype in six to eight weeks and is on track to produce its showcase
full-scale fillet of 100% meat in early in 2023.

 

Che Connon, Chief Executive of 3DBT, said: "We are extremely pleased with the
results of our first prototype which has exceeded our expectations in terms of
integrity, aroma, texture and more. We believe our prototypes to be some of
the first fillets of cultivated meat in the world, representing a
ground-breaking development for the industry.

 

"A further industry milestone is that our prototypes are 100% animal meat,
having nativelike structure without the need for plant-based scaffolds. This
structure without scaffold was achieved through culturing the fillets with
City-mix(TM), our patented animal-free media which represents the next
generation in growth agents. The success of our prototypes puts us firmly on
the path to producing our first showcase fillet of meat and we are hugely
excited for the future."

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com/)  or contact:

 BSF Enterprise PLC                       Via SEC Newgate below
 Geoff Baker - Non-Executive Director

 Che Connon - Executive Director

 Shard Capital (Broker)
 Damon Heath                              0203 971 7000

 SEC Newgate (Financial Communications)
 Bob Huxford                              020 3757 6882

 Elisabeth Cowell                         BSF@secnewgate.co.uk

 George Esmond

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cell-based tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

 

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas to help restore
vision to millions of people. Building on this success, it aims to
produce the UK's first high quality lab-grown meat from its laboratory in
Newcastle the next 12 months, transforming the meat-production industry
towards an ethical and sustainable practice.

 

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
through M&A. It aims to acquire a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and license
out the IP to manufacturers, wholesalers and distributors to help manufacture
the products at scale.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPGPWGUPPPGC